Proenzyme psa for the early detection of prostate cancer in the 2.5–4.0 ng/ml total psa range: preliminary analysis
Authors:
- Daniel W ChanDCDaniel W Chan
- Stephen D MikolajczykSMStephen D Mikolajczyk
- Harry G RittenhouseHRHarry G Rittenhouse
- Cindy L EvansCECindy L Evans
- Harry J LintonHLHarry J Linton
- Leslie A MangoldLMLeslie A Mangold
- Phaedre MohrPMPhaedre Mohr
- Georg BartschGBGeorg Bartsch
- Helmut KlockerHKHelmut Klocker
- Wolfgang HorningerWHWolfgang Horninger
- Alan W PartinAPAlan W Partin
- 1 February 2003
- Vol. 61 (2) , 274-276
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate-specific antigen levels of 2 to 4 nanograms per milliliterUrology, 2002
- Robustness of Free Prostate Specific Antigen Measurements to Reduce Unnecessary Biopsies in the 2.6 to 4.0 ng./ml. RangeJournal of Urology, 2002
- Percent Free Prostate Specific Antigen in the Total Prostate Specific Antigen 2 to 4 ng./ml. Range Does Not Substantially Increase the Number of Biopsies Needed to Detect Clinically Significant Prostate Cancer Compared to the 4 to 10 ng./ml. RangeJournal of Urology, 2002
- Free prostate-specific antigen in serum is becoming more complexUrology, 2002
- LONG-TERM BIOCHEMICAL DISEASE-FREE AND CANCER-SPECIFIC SURVIVAL FOLLOWING ANATOMIC RADICAL RETROPUBIC PROSTATECTOMYUrologic Clinics of North America, 2001
- “BPSA,” a specific molecular form of free prostate-specific antigen, is found predominantly in the transition zone of patients with nodular benign prostatic hyperplasiaUrology, 2000
- Use of the Percentage of Free Prostate-Specific Antigen to Enhance Differentiation of Prostate Cancer From Benign Prostatic DiseaseJAMA, 1998
- A precursor form of PSA (pPSA) is a component of the free PSA in prostate cancer serumUrology, 1997
- Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurementsJAMA, 1997
- Longitudinal screening for prostate cancer with prostate-specific antigen1996